DDInter948 DDInter689
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_. Ethambutol was granted FDA approval on 6 November 1967.
Ethambutol {u} (Compound) upregulates {v} (Gene) KLHL21
Ethambutol {u} (Compound) downregulates {v} (Gene) TARBP1
Ethambutol {u} (Compound) causes {v} (Side Effect) Neutropenia
Ethambutol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etanercept
Ethambutol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tinidazole
Ethambutol {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Ethambutol (Compound) upregulates KLHL21 (Gene)
Ethambutol (Compound) downregulates TARBP1 (Gene)
Ethambutol (Compound) causes Neutropenia (Side Effect)
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Etanercept
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole
Ethambutol may lead to a major life threatening interaction when taken with Teriflunomide